Diagnostics and treatment of dementia in Parkinson's disease

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 108, Issue 6, 2008, Pages 91-97

  Levin, O S ^a   Batukaeva, L A ^a   Smolentseva, I G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 49949088266     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Russian source
2. Russian source
3. Russian source
4. Russian source
5. Russian source
6. Russian source
7. Russian source
8. Russian source
9. Russian source
10. Russian source
11. Russian source
12. Russian source
13. Aarsland D., Andersen K., Larsen J.P. et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387-392.
14. Aarsland D., Bronnick K., Ehrt U. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiat 2007; 78: 36-42.
15. Ballard C., Lane R., Barone P. et al. Cardiac safety of rivastigrnine in Lewy body and Parkinson's disease dementia. Int J Clin Pract 2006; 60: 639-645.
16. Ballard C. G., Chalmers K.A., Todd C. et al. Cholinesterase inhibitors reduce cortical amyloid-beta in dementia with Lewy bodies. Neurology 2007; 68: 1726-1729.
17. Braak H., Del Tredici K., Bratzke H. et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002; 249: 3: 1-5.
18. Bronnick K., Emre M., Lane R. et al. Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease. J Neurol Neurosurg Psychiat 2007; 78: 1064-1068.
19. Burn D.I., Emre M., McKeith I.G. et al. Effects of rivastigrnine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006; 21: 1899-1907.
20. Burn D.J., Rowan E.N., Allan L.M. et al. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. Neurol Neurosurg Psychiat 2006; 77: 585-589.
21. Caviness J.N., Driver-Dunckley E., Connor D.J. et al. Defining mild cognitive impairment in Parkinson disease. Mov Disord 2007; 22: 1272-1277.
22. Cummings J.L. Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease. J Neurol Neurosurg Psychiat 2005; 76: 903-904.
23. Dubois B., Burn D., Goetz C. et al. Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force. Mov Disord 2007; 22: 2314-2324.
24. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003; 2: 229-237.
25. Emre M., Aarsland D., Albanese A. et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-2518.
26. Emre M., Aarsland D., Brown R. et al. Clinical diagnostic criteria for dementia associated with Parkinson disease. Mov Disord 2007; 22: 1689-1707.
27. Feldman H., Lane R., on behalf of the Study 304 Group. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. J Neurol Neurosurg Psychiat 2007; 78: 1056-1063.
28. Ferreri F., Agbokou C., Gauthier S. Recognition and management of neuropsychiatric complications in Parkinson's disease. CMAJ 2006; 175: 1545-1552.
29. Galvin J.E., Pollack J., Morris J.C. Clinical phenotype of Parkinson disease dementia. Neurology 2006; 67: 1605-1611.
30. Hely M.A., Morris J. G., Reid W. G. et al. Sydney multicenter study of Parkinson's disease. Mov Disord 2005; 20: 190-199.
31. Hilker R., Thomas A. V., Klein J. C. et al. Dementia in Parkinson disease: Functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 65: 1716-1722.
32. Inzellberg R., Bonuccelli U., Schechtman E. Association between amantadine and onset of dementia in Parkinson disease. Mov Disord 2006; 21: 1375-1379.
33. Kurlan R., Cummings J., Raman R. et al. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007; 68: 1356-1363.
34. Lippa C.F., Duda J.E., Grossman M. et al. DLB and PDD boundary issues: Diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007; 68: 812-819.
35. Miyasaki J.M., Shannon K., Voon V. et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 996-1002.
36. Molloy S.A., Rowan E.N., O'Brien J. T. et al. Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiat 2006; 77: 1323-1328.
37. Parkinson J. An essay on the shaking palsy. London 1817; 66.
38. Postuma R.B., Lang A.E., Massicotte-Marquez J. et al. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 2006; 66: 845-851.
39. Roland J.R., Rigby J., Harper A.C. et al. Cardiovascular monitoring with acetylcholinesterase inhibitors. Adv Psych Treat 2007; 13: 178-184.
40. Wesnes K.A., McKeith I., Edgar C. et al. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005; 65: 1654-1656.
41. Williams-Gray C.H., Foltynie T., Brayne C.E.G. et al. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007; 130: 1787-1798.